Research programme: inhibitors of peptide deformylase and Mur pathway enzymes - Novartis/Pfizer

Drug Profile

Research programme: inhibitors of peptide deformylase and Mur pathway enzymes - Novartis/Pfizer

Alternative Names: 415; LBM-415; NVP-PDF-713; PDF7; VIC-104959; VRC 3852; VRC-3324; VRC-3375; VRC-4307; VRC-4887

Latest Information Update: 13 Mar 2008

Price : $50

At a glance

  • Originator Novartis; Pfizer
  • Class Hydroxamic acids; Peptides
  • Mechanism of Action Cell wall inhibitors; Peptide deformylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Community-acquired pneumonia

Most Recent Events

  • 11 Sep 2005 Vicuron Pharmaceuticals has been acquired and merged into Pfizer
  • 04 Mar 2005 Suspended - Phase-I for Community-acquired pneumonia in USA (unspecified route)
  • 16 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial infections antimicrobial activity, pharmacodynamics and pharmacokinetics section ,,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top